Skip to main content
Supplement Research and Comparison WebsiteBest Price Guarantee
Supplement Research and Comparison Website

Abstract

Positive effects of fermented foods consumption on humans have stimulated lots of research attention. In this study, we investigated the probiotic potentials, antagonistic activities, and safety properties of Lactobacillus brevis gp104 isolated from Iranian traditional cheese. The results showed that the strain had high resistance to acidic conditions, simulated gastric and intestinal fluid. L. brevis gp104 was able to assimilate cholesterol from the medium; 41% in medium without bile salts and 58% in medium with bile salts. The potential of this strain was relatively low in phytate hydrolyzation and 62.02% hydrophobicity, 40.2% auto-aggregation, and 48.3% co-aggregation were observed. The adhesion value of L. brevis gp104 to adenocarcinoma Caco-2 cells was 13.4% that was also confirmed by scanning electron microscopy (SEM). Antibacterial effect of L. brevis fg104 was imposed against pathogenic strains (Escherichia coli ATCC 25922, Pseudomonas aeruginosa PTCC 1707, Salmonella typhimurium PTCC 1609, and Staphylococcus aureus ATCC 25923) and the most sensitive strain S. aureus. L. brevis gp104 was able to compete (52%), inhibit (47%) and displace (21%) the adhesion of S. aureus to Caco-2 cells. L. brevis gp104 did not show haemolytic or DNase activity, which confirms its safety aspects. Therefore, L. brevis gp104 was demonstrated promising properties for its potential health benefits for its application as novel bio-therapeutic and bio-preservation agents.

Keywords: Caco-2 cells; Cholesterol; Microscopy; Probiotics; Safety.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Lactobacillus brevisEnhanced Acidic Condition ResistanceBeneficial
Large
Lactobacillus brevisImproved Cholesterol LevelsBeneficial
Moderate
Lactobacillus brevisIncreased Antibacterial ActivityBeneficial
Large
Lactobacillus brevisNo Haemolytic or DNase ActivityBeneficial
Large
Lactobacillus brevisReduced Pathogen AdhesionBeneficial
Moderate
Lactobacillus brevis LB01Absence of Hemolytic ActivityBeneficial
Moderate
Lactobacillus brevis LB01Increased Antibacterial Activity Against Pathogenic StrainsBeneficial
Large
Lactobacillus brevis LB01Reduced Cholesterol LevelsBeneficial
Moderate
Lactobacillus brevis LB01Reduced Pathogen AdhesionBeneficial
Moderate
Lactobacillus brevis Lbr-35Ensured Safety for Human ConsumptionBeneficial
Large
Lactobacillus brevis Lbr-35Improved Gastrointestinal ResilienceBeneficial
Moderate
Lactobacillus brevis Lbr-35Improved Gut AdhesionBeneficial
Moderate
Lactobacillus brevis Lbr-35Increased Antibacterial Activity Against PathogensBeneficial
Large
Lactobacillus brevis Lbr-35Reduced Total Cholesterol LevelsBeneficial
Moderate
Lactobacillus brevis SD-5214Adhesion to Caco-2 CellsBeneficial
Moderate
Lactobacillus brevis SD-5214Enhanced Acidic Condition ResistanceBeneficial
Large
Lactobacillus brevis SD-5214Enhanced Food SafetyBeneficial
Large
Lactobacillus brevis SD-5214Improved Cholesterol LevelsBeneficial
Moderate
Lactobacillus brevis SD-5214Increased Antibacterial Activity Against PathogensBeneficial
Large
Lactobacillus brevis SD-5214Increased Cell Surface HydrophobicityBeneficial
Moderate
Lactobacillus brevis SD-5214Reduced Pathogen AdhesionBeneficial
Moderate
Lactobacillus brevis VPro 18Adhesion to Caco-2 CellsBeneficial
Moderate
Lactobacillus brevis VPro 18Enhanced Antibacterial EffectBeneficial
Moderate
Lactobacillus brevis VPro 18Improved Cholesterol LevelsBeneficial
Moderate
Lactobacillus brevis VPro 18Improved Safety ProfileBeneficial
Large
Lactobacillus brevis VPro 18Increased Acid ResistanceBeneficial
Large
Lactobacillus brevis VPro 18Reduced Staphylococcus aureus ColonizationBeneficial
Moderate
Back to top